Hepatobiliary Neoplasia 3: Response or Resistance to Therapy
Nov
2026
Description
This session examines mechanisms of treatment resistance in hepatobiliary cancers, including tumor microenvironment and immune evasion pathways driving resistance to immunotherapy.
Presentations
5:00 PM
- 5:15 PM
Convention Center - Bluebird Ballroom 1C
Donor HBV exposure status is associated with increased recurrence of hepatocellular carcinoma after liver transplantation: a national registry analysis with propensity-score and weighting-based competing-risks models
Leandro Sierra, MD, | Abstract Presenter
5:15 PM
- 5:30 PM
Convention Center - Bluebird Ballroom 1C
Biliary loss of primary cilia and Pten drive intrahepatic cholangiocarcinoma resembling a human subtype with a poor prognosis
Geoffrey g McCaughan, MD, PhD | Abstract Presenter
5:30 PM
- 5:45 PM
Convention Center - Bluebird Ballroom 1C
AARS2-Mediated Lactylation Drives CCR4⁺ Treg Recruitment and Immunotherapy Resistance in Hepatocellular Carcinoma
Chunyao Fang, PhD | Abstract Presenter
5:45 PM
- 6:00 PM
Convention Center - Bluebird Ballroom 1C
Lipid-Associated SPP1⁺Macrophages Drive Attenuated Responses to Immune Checkpoint Inhibitors in MASLD-Associated Hepatocellular Carcinoma
Enrui Xie, MD | Abstract Presenter
6:00 PM
- 6:15 PM
Convention Center - Bluebird Ballroom 1C
Integrating bulk, single-cell, and spatial transcriptomics reveals potential biomarkers of tertiary lymphoid structure-related genes in prognosis and immunotherapy response in hepatocellular carcinoma
Yuexi Yu | Abstract Presenter
6:15 PM
- 6:30 PM
Convention Center - Bluebird Ballroom 1C
ZDHHC4+ CAFs establish an immunosuppressive CMxT niche in hepatocellular carcinoma
Suiqing Zhou, PhD | Abstract Presenter
